New Probiotic Strain Safely Boosts Immunity and Improves Cholesterol in 8-Week Trial
L. reuteri LR08 enhanced immune markers, lowered cholesterol, and improved gut health without safety concerns in healthy adults.
Summary
A new probiotic strain called Limosilactobacillus reuteri LR08 safely improved multiple health markers in a rigorous 8-week clinical trial. Researchers gave 48 healthy adults either the probiotic or placebo daily, finding significant improvements in immune function, cholesterol levels, and gut bacteria diversity. The probiotic increased protective antibodies in saliva, reduced harmful LDL cholesterol and uric acid levels, and enriched beneficial gut bacteria. Comprehensive safety testing confirmed no concerning genes or toxic effects, making this strain a promising option for supporting metabolic health and immune function.
Detailed Summary
Probiotics continue showing promise for enhancing human health, but safety and efficacy vary dramatically between strains. This comprehensive study evaluated a specific strain, Limosilactobacillus reuteri LR08, using both genomic safety analysis and human clinical testing.
Researchers conducted whole-genome sequencing to verify the strain contained no harmful genes, then tested 48 healthy adults in a randomized, double-blind, placebo-controlled trial. Participants received either 30 billion CFU of LR08 daily or placebo for eight weeks while researchers monitored blood markers, immune function, and gut bacteria composition.
The results were impressive across multiple health domains. LR08 significantly reduced serum uric acid and LDL cholesterol levels compared to baseline measurements. Immune function improved markedly, with increased salivary antibodies including IgA, IgM, and calprotectin. Gut microbiota analysis revealed enhanced bacterial diversity and enrichment of beneficial genera like Blautia and Romboutsia, along with improved carbohydrate metabolism pathways.
For longevity-focused individuals, these findings suggest LR08 could support healthy aging through multiple mechanisms: improved cholesterol profiles may reduce cardiovascular disease risk, enhanced immune function could provide better infection resistance, and optimized gut bacteria support overall metabolic health. The comprehensive safety profile makes this strain particularly appealing for long-term use.
However, this study involved only healthy adults over eight weeks, so effects in other populations or with longer supplementation remain unknown. The relatively small sample size also limits generalizability, though the rigorous methodology strengthens confidence in the findings.
Key Findings
- LR08 probiotic significantly reduced LDL cholesterol and uric acid levels in healthy adults
- Salivary antibodies IgA, IgM, and calprotectin increased, indicating enhanced immune function
- Gut bacteria diversity improved with enrichment of beneficial Blautia and Romboutsia genera
- Comprehensive genomic analysis confirmed absence of harmful genes or antibiotic resistance
- No adverse effects observed during 8-week supplementation period
Methodology
Randomized, double-blind, placebo-controlled trial with 48 healthy adults receiving either 30 billion CFU LR08 or placebo daily for 8 weeks. Included comprehensive genomic sequencing, in vitro safety testing, and 16S rRNA gut microbiota analysis.
Study Limitations
Study limited to healthy adults over 8 weeks with relatively small sample size. Effects in clinical populations, optimal dosing, and long-term safety beyond 8 weeks require further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.